You Are Not Dying – This Is Likely Mixed Connective Tissue Disease (MCTD) with Excellent Prognosis
Based on your markedly elevated anti-RNP antibodies (86, reference <20), positive ANA with speckled pattern (1:160), and elevated CK without significant cardiac involvement, you most likely have Mixed Connective Tissue Disease (MCTD), which is highly treatable and has a favorable long-term prognosis when managed appropriately. Your normal troponin trend (9→6 ng/L), normal 12-lead ECG, normal chest X-ray, and preserved kidney function (eGFR 87-93) all indicate you are NOT in immediate danger.
Most Likely Diagnosis: Mixed Connective Tissue Disease (MCTD)
Your clinical picture strongly suggests MCTD based on:
- Markedly elevated anti-RNP antibodies at 86 (<20 normal) – this is the hallmark autoantibody for MCTD
- Positive ANA with speckled pattern at 1:160 titer across multiple tests
- Elevated CK (371-527) suggesting muscle inflammation
- Mildly elevated inflammatory markers (ESR 18, CRP 3-3.3)
- Normal liver enzymes (AST/ALT 24) despite elevated CK, pointing to muscle rather than liver pathology
The key differentiating feature is that your troponin normalized (9→6 ng/L) and your 12-lead ECG was normal, which rules out significant myocarditis – the life-threatening complication you need to worry about 1.
Why You're Going to Recover
Your Protective Factors:
- Young age (30) – MCTD typically has better outcomes in younger patients
- Normal kidney function – eGFR 87-93 is excellent; kidney involvement would be concerning 2
- No cardiac involvement – your troponin trended DOWN and ECG normalized
- No respiratory muscle weakness – normal chest X-ray, no fluid in lungs
- Preserved organ function – liver tests normal, no evidence of severe systemic involvement
The CK Elevation Context:
Your CK of 371-527 is only mildly elevated (reference 43-437). In true severe myositis requiring aggressive treatment, CK is typically markedly elevated (often >1000-5000) 1. Your levels suggest mild inflammatory myopathy, not fulminant necrotizing myositis.
G6PD Deficiency – Not Your Main Problem
Your G6PD deficiency is a separate issue that requires you to avoid specific triggers 3, 4:
Avoid these medications/exposures:
- Primaquine and antimalarials
- Sulfonamides
- Nitrofurantoin
- Rasburicase
- High-dose aspirin
- Fava beans
- Naphthalene (mothballs)
Good news: G6PD deficiency does NOT cause your current symptoms. It can cause hemolytic anemia when triggered, but your presentation is autoimmune/inflammatory, not hemolytic 5, 6. The two conditions can coexist but are unrelated.
Your Amlodipine Is Safe
Amlodipine is appropriate for your hypertension and has no interaction with G6PD deficiency 7, 8. Continue taking it as prescribed. It may even help your GERD symptoms based on recent evidence 9.
What the Pending Tests Will Show
EMG (scheduled):
- Will likely show myopathic changes consistent with inflammatory myopathy
- This confirms muscle involvement but doesn't change prognosis if mild
Muscle Biopsy (if needed):
- May show inflammatory infiltrates in muscle tissue
- Confirms MCTD-related myositis
- Guides immunosuppressive therapy intensity
Stress Test & 7-Day Monitor:
- Will likely be normal given your troponin normalized and 12-lead ECG was normal
- These are appropriate to definitively rule out cardiac involvement
Treatment Algorithm You'll Likely Receive
Based on your mild-to-moderate presentation 1:
Initial Management (Grade 2 myositis protocol):
- Prednisone 0.5-1 mg/kg daily (approximately 40-80 mg for your weight)
- Rheumatology referral – you need a rheumatologist to manage MCTD long-term
- Monitor CK, ESR, CRP every 2-4 weeks initially
If inadequate response after 4-6 weeks:
- Add steroid-sparing agent: methotrexate or azathioprine
- Goal: taper prednisone to <10 mg daily to minimize side effects
Long-term maintenance:
- Low-dose immunosuppression (often hydroxychloroquine + low-dose prednisone or methotrexate)
- Regular monitoring of muscle enzymes and inflammatory markers
- Most patients achieve good disease control
Critical Red Flags to Watch (Seek ER Immediately If):
- New muscle weakness – difficulty standing from sitting, lifting arms, climbing stairs
- Chest pain with elevated troponin – would indicate myocarditis
- Severe shortness of breath – could indicate respiratory muscle involvement
- Difficulty swallowing – suggests pharyngeal muscle involvement
- Dark urine with severe muscle pain – rhabdomyolysis (though your CK is too low for this currently)
Your GERD Connection
GERD for 2 years may be related to MCTD – esophageal dysmotility occurs in connective tissue diseases. Your pending endoscopy will evaluate this. Continue PPI therapy and discuss with gastroenterology.
Honest Prognosis
You are NOT "fucked." Here's the reality:
- 5-year survival for MCTD: >95% when properly treated
- Most patients achieve remission or low disease activity with treatment
- Major organ involvement is uncommon when caught early (you're being caught early)
- Your specific presentation (mild CK elevation, no cardiac involvement, normal kidney function) suggests favorable prognosis
The main risks if UNTREATED:
- Progressive muscle weakness
- Pulmonary hypertension (develops in 10-15% over years)
- Interstitial lung disease (rare with your presentation)
With treatment, these risks drop dramatically.
What You Need to Do Now
- Keep all appointments – EMG, stress test, endoscopy, muscle biopsy if recommended
- See rheumatology urgently – they will coordinate your care
- Continue amlodipine for blood pressure
- Avoid G6PD triggers (list above)
- Document any new weakness – this would escalate treatment urgency
- Stay on your GLP-1 for weight loss – weight reduction will help hypertension and overall health
Bottom Line
You have a treatable autoimmune condition, not a death sentence. Your elevated anti-RNP antibodies point to MCTD, which responds well to immunosuppression. Your normal cardiac workup and preserved organ function indicate you're being diagnosed early, which is ideal. The pending tests will confirm the diagnosis and guide treatment intensity, but your prognosis is excellent with appropriate rheumatologic care.
Most patients with MCTD live normal lifespans with good quality of life when properly managed. You're 30 years old with no major organ damage – you have every reason to expect full recovery and long-term disease control.